Details der Publikation - Increase recombinant antibody yields through optimizing vector design and production process in CHO cells

Increase recombinant antibody yields through optimizing vector design and production process in CHO cells

Abstract Chinese hamster ovary (CHO) cells are the most commonly used host cells for the production of recombinant monoclonal antibodies (mAbs) due to their several advantages. Although the yields of recombinant mAbs can be greatly increased by some strategies, such as medium formulation, culture conditions, and cell engineering, most studies focused on either upstream design or downstream processes. In the present study, we first expressed recombinant adalimumab through combination of the vector design and production process optimization in CHO cells. Bicistronic vector, monocistronic vector, and dual promoter vector were constructed, and the production process was optimized using low-temperature and fed-batch culture. The results showed that the dual promoter vector exhibited the highest yield under the transient and stable transfected cells among three different vector systems in CHO cells. In addition, low-temperature and fed-batch culture could further improve the yields of adalimumab. The purified antibody displayed tumor necrosis factor-α (TNF-α) binding activity. In conclusion, combination of expression vector design and production process optimization can achieve higher expression of recombinant mAbs in CHO cells. Key points • The dual promoter vector is more effective for expressing recombinant antibodies. • The yields of antibodies are related to the LC chain expression level. • Low-temperature and feed addition can promote antibody production..

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:106
Enthalten in:	Applied microbiology and biotechnology - 106(2022), 13-16 vom: 05. Juli, Seite 4963-4975

Sprache:	Englisch

Beteiligte Personen:	Yang, Yongxiao [VerfasserIn] Li, Zhengmei [VerfasserIn] Li, Qin [VerfasserIn] Ma, Kai [VerfasserIn] Lin, Yan [VerfasserIn] Feng, Huigen [VerfasserIn] Wang, Tianyun [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	58.30$jBiotechnologie 42.30$jMikrobiologie
Themen:	Adalimumab CHO cells Production process Purification and identification Recombinant antibody Vector optimization

RVK:	RVK Klassifikation ELIB09 ELIB10 ELIB24 ELIB41 ELIB22

Anmerkungen:	© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

doi:	10.1007/s00253-022-12051-5

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2131467168

Internformat


LEADER	01000naa a22002652 4500
001	OLC2131467168
003	DE-627
005	20230506043451.0
007	cr uuu---uuuuu
008	230506s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00253-022-12051-5 \|2 doi
035			\|a (DE-627)OLC2131467168
035			\|a (DE-He213)s00253-022-12051-5-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 570 \|q VZ
084			\|a ELIB09 \|q VZ \|2 rvk
084			\|a ELIB10 \|q VZ \|2 rvk
084			\|a ELIB24 \|q VZ \|2 rvk
084			\|a ELIB41 \|q VZ \|2 rvk
084			\|a ELIB22 \|q VZ \|2 rvk
084			\|a 58.30$jBiotechnologie \|2 bkl
084			\|a 42.30$jMikrobiologie \|2 bkl
100	1		\|a Yang, Yongxiao \|e verfasserin \|4 aut
245	1	0	\|a Increase recombinant antibody yields through optimizing vector design and production process in CHO cells
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022
520			\|a Abstract Chinese hamster ovary (CHO) cells are the most commonly used host cells for the production of recombinant monoclonal antibodies (mAbs) due to their several advantages. Although the yields of recombinant mAbs can be greatly increased by some strategies, such as medium formulation, culture conditions, and cell engineering, most studies focused on either upstream design or downstream processes. In the present study, we first expressed recombinant adalimumab through combination of the vector design and production process optimization in CHO cells. Bicistronic vector, monocistronic vector, and dual promoter vector were constructed, and the production process was optimized using low-temperature and fed-batch culture. The results showed that the dual promoter vector exhibited the highest yield under the transient and stable transfected cells among three different vector systems in CHO cells. In addition, low-temperature and fed-batch culture could further improve the yields of adalimumab. The purified antibody displayed tumor necrosis factor-α (TNF-α) binding activity. In conclusion, combination of expression vector design and production process optimization can achieve higher expression of recombinant mAbs in CHO cells. Key points • The dual promoter vector is more effective for expressing recombinant antibodies. • The yields of antibodies are related to the LC chain expression level. • Low-temperature and feed addition can promote antibody production.
650		4	\|a CHO cells
650		4	\|a Recombinant antibody
650		4	\|a Adalimumab
650		4	\|a Vector optimization
650		4	\|a Production process
650		4	\|a Purification and identification
700	1		\|a Li, Zhengmei \|4 aut
700	1		\|a Li, Qin \|4 aut
700	1		\|a Ma, Kai \|4 aut
700	1		\|a Lin, Yan \|4 aut
700	1		\|a Feng, Huigen \|4 aut
700	1		\|a Wang, Tianyun \|0 (orcid)0000-0002-0793-1006 \|4 aut
773	0	8	\|i Enthalten in \|t Applied microbiology and biotechnology \|d Springer Berlin Heidelberg, 1975 \|g 106(2022), 13-16 vom: 05. Juli, Seite 4963-4975 \|h Online-Ressource \|w (DE-627)265509564 \|w (DE-600)1464336-4 \|w (DE-576)074889737 \|x 1432-0614 \|7 nnns
773	1	8	\|g volume:106 \|g year:2022 \|g number:13-16 \|g day:05 \|g month:07 \|g pages:4963-4975
856	4	0	\|u https://dx.doi.org/10.1007/s00253-022-12051-5 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_381
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2360
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB09
936	r	v	\|a ELIB10
936	r	v	\|a ELIB24
936	r	v	\|a ELIB41
936	r	v	\|a ELIB22
936	b	k	\|a 58.30$jBiotechnologie \|q VZ \|0 106405365 \|0 (DE-625)106405365
936	b	k	\|a 42.30$jMikrobiologie \|q VZ \|0 106419501 \|0 (DE-625)106419501
951			\|a AR
952			\|d 106 \|j 2022 \|e 13-16 \|b 05 \|c 07 \|h 4963-4975

Increase recombinant antibody yields through optimizing vector design and production process in CHO cells

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände